Papel da deambulação na prevenção do tromboembolismo venoso em pacientes clínicos: onde estamos?
Role of ambulation to prevent venous thromboembolism in medical patients: where do we stand?
Maria Chiara Chindamo; Marcos Arêas Marques
Resumo
Palavras-chave
Abstract
Abstract: Venous thromboembolism (VTE) encompasses the spectrum of manifestations of deep venous thrombosis and/or pulmonary embolism and is a common, serious, and preventable complication in hospitalized patients. Although immobility plays an important role in determining VTE risk in medical patients, no clear and uniform criteria exist to guide clinicians in assessing immobility. The variation in the descriptions that do exist makes it difficult to interpret and compare the results of randomized clinical trials with respect to the influence of different levels of immobility on the magnitude of VTE risk and the role that early ambulation as an isolated factor plays in prevention of such events. Understanding these limitations is a prerequisite for the proper use and interpretation of VTE risk assessment tools and for indicating the best strategy for preventing venous thrombosis in hospitalized medical patients. The objective of this study was to review the main evidence reported in the literature on the role of ambulation in prevention of VTE.
Keywords
References
Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ. 1991;302(6778):709-11. http://dx.doi.org/10.1136/bmj.302.6778.709. PMid:2021744.
Alikhan R, Peters F, Wilmott R, Cohen AT. Fatal pulmonary embolism in hospitalized patients: a necropsy review. J Clin Pathol. 2004;57(12):1254-7. http://dx.doi.org/10.1136/jcp.2003.013581. PMid:15563663.
Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2, Suppl 2):e195S-226S. http://dx.doi.org/10.1378/chest.11-2296. PMid:22315261.
Dobesh P. The importance of appropriate prophylaxis for the prevention of venous thromboembolism in at-risk medical patients. Int J Clin Pract. 2010;64(11):1554-62. http://dx.doi.org/10.1111/j.1742-1241.2010.02447.x. PMid:20846203.
Weill-Engerer S, Meaume S, Lahlou A, et al. Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc. 2004;52(8):1299-304. http://dx.doi.org/10.1111/j.1532-5415.2004.52359.x. PMid:15271117.
Oliveira ALML, Marques MA. Venous thromboembolism prophylaxis in pregnancy. J Vasc Bras. 2016;15(4):293-301. PMid:29930607.
Amin AN, Girard F, Samama MM. Does ambulation modify venous thromboembolism risk in acutely ill medical patients? Thromb Haemost. 2010;104(5):955-61. PMid:20838741.
Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153(1):8-18. http://dx.doi.org/10.7326/0003-4819-153-1-201007060-00004. PMid:20621900.
Motykie GD, Caprini JA, Arcelus JI, et al. Risk factor assessment in the management of patients with suspected deep venous thrombosis. Int Angiol. 2000;19(1):47-51. PMid:10853685.
Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000;160(22):3415-20. http://dx.doi.org/10.1001/archinte.160.22.3415. PMid:11112234.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809-15. http://dx.doi.org/10.1001/archinte.160.6.809. PMid:10737280.
Ye F, Bell LN, Mazza J, Lee A, Yale SH. Variation in definitions of immobility in pharmacological thromboprophylaxis clinical trials in medical inpatients: a systematic review. Clin Appl Thromb Hemost. 2018;24(1):13-21. http://dx.doi.org/10.1177/1076029616677802. PMid:28301904.
Hull RD. Relevance of immobility and importance of risk assessment management for medically ill patients. Clin Appl Thromb Hemost. 2013;19(3):268-76. http://dx.doi.org/10.1177/1076029612452781. PMid:22826444.
Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis. 1996;26(Suppl 2):49-56. PMid:8707167.
Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003;145(4):614-21. http://dx.doi.org/10.1067/mhj.2003.189. PMid:12679756.
Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo-controlled trial. BMJ. 2006;332(7537):325-9. http://dx.doi.org/10.1136/bmj.38733.466748.7C. PMid:16439370.
Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-9. http://dx.doi.org/10.1161/01.CIR.0000138928.83266.24. PMid:15289368.
Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793-800. http://dx.doi.org/10.1056/NEJM199909093411103. PMid:10477777.
Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-94. http://dx.doi.org/10.1016/S0140-6736(08)60202-0. PMid:18242412.
Kerbauy MN, Moraes FY, Kerbauy LN, Conterno LO, El-Fakhouri S. Venous thromboprophylaxis in medical patients: an application review. Rev Assoc Med Bras. 2013;59(3):258-64. http://dx.doi.org/10.1016/j.ramb.2012.11.008. PMid:23680273.
Stuck AK, Spirk D, Schaudt J, Kucher N. Risk assessment models for venous thromboembolism in acutely ill medical patients: a systematic review. Thromb Haemost. 2017;117(4):801-8. http://dx.doi.org/10.1160/TH16-08-0631. PMid:28150851.
Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450-7. http://dx.doi.org/10.1111/j.1538-7836.2010.04044.x. PMid:20738765.
Spyropoulos AC, Anderson FA Jr, Fitzgerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706-14. http://dx.doi.org/10.1378/chest.10-1944. PMid:21436241.
Rocha AT, Paiva EF, Lichtenstein A, Milani R Jr, Cavalheiro CF, Maffei FH. Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients. Vasc Health Risk Manag. 2007;3(4):533-53. PMid:17969384.
Amin A, Lin J, Ryan A. Lack of thromboprophylaxis across the care continuum in US medical patients. Hosp Pract. 2010;38(3):17-25. http://dx.doi.org/10.3810/hp.2010.06.311. PMid:20499769.
Amin AN, Varker H, Princic N, Lin J, Thompson S, Johnston S. Duration of venous thromboembolism risk across a continuum in medically Ill hospitalized patients. J Hosp Med. 2012;7(3):231-8. http://dx.doi.org/10.1002/jhm.1002. PMid:22190427.
Hull RD, Merali T, Mills A, Stevenson AL, Liang J. Venous thromboembolism in elderly high-risk medical patients: time course of events and influence of risk factors. Clin Appl Thromb Hemost. 2013;19(4):357-62. http://dx.doi.org/10.1177/1076029613481105. PMid:23610237.
Cohen AT, Spiro TE, Büller HR, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis. 2011;31(4):407-16. http://dx.doi.org/10.1007/s11239-011-0549-x. PMid:21359646.
Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167-77. http://dx.doi.org/10.1056/NEJMoa1110899. PMid:22077144.
Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely Ill medical patients. N Engl J Med. 2016;375(6):534-44. http://dx.doi.org/10.1056/NEJMoa1601747. PMid:27232649.
Raskob GE, Spyropoulos AC, Zurbek J, et al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE: design, rationale, and clinical implications. Thromb Haemost. 2016;115(6):1240-8. http://dx.doi.org/10.1160/TH15-09-0756. PMid:26842902.
Spyropoulos AC, Ageno W, Albers GW, et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018;379(12):1118-27. http://dx.doi.org/10.1056/NEJMoa1805090. PMid:30145946.
Zomorodi M, Topley D, McAnaw M. Developing a mobility protocol for early mobilization of patients in a surgical/trauma ICU. Crit Care Res Pract. 2012;2012:964547. http://dx.doi.org/10.1155/2012/964547. PMid:23320154.
Talec P, Gaujoux S, Samama CM. Early ambulation and prevention of post-operative thromboembolic risk. J Vasc Surg. 2016;153(6S):S11-4. PMid:27789264.
Pashikanti L, Von Ah D. Impact of early mobilization protocol on the medical-surgical inpatient population: an integrated review of literature. Clin Nurse Spec. 2012;26(2):87-94. http://dx.doi.org/10.1097/NUR.0b013e31824590e6. PMid:22336934.
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email